DPP-4 inhibitors were not associated with increased risk for pancreatic cancer in the direct meta-analysis (Peto odds ratio 0.65; 95% CI 0.35–1.21) (Fig. 2A– Forest plot for association between DPP-4 inhibitors and pancreatic cancer). The gene discussed is DPP4; the disease is familial pancreatic carcinoma.